Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01921296 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients
A Phase 2 study, sponsored by Lynn Henry.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01921296: Clinical Trial Phase 2 study, sponsored by Lynn Henry.
NCT01921296 is a Phase 2 study that was terminated before completion, run by Lynn Henry. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01921296, a Phase 2 study, was terminated before completion, sponsored by Lynn Henry.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Many women with breast cancer who are treated with aromatase inhibitor medications develop difficulty sleeping and fatigue during treatment. Some examples of aromatase inhibitor medications include anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara). Frequently, sleeping pills do not work very well to improve sleep. Cyclobenzaprine (Flexeril) is a medication that was originally developed to treat muscle spasms. It may also improve sleep in patients with chronic pain disorders, such as fibromyalgia. In this study we are testing to see if cyclobenzaprine at bedtime will help improve sleep in women treated with aromatase inhibitors.
Interventions
- DRUG Cyclobenzaprine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01921296
The ClinicalTrials.gov registry entry for NCT01921296 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lynn Henry, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cyclobenzaprine is the first listed.
NCT01921296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01921296 about?
NCT01921296 is a clinical study titled "Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients". Many women with breast cancer who are treated with aromatase inhibitor medications develop difficulty sleeping and fatigue during treatment. Some examples of aromatase inhibitor medications include anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara). Frequently, sleeping pills do n...
What is the current status of trial NCT01921296?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2013-08. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01921296?
The interventions under investigation include: Cyclobenzaprine (DRUG).
Who is sponsoring clinical trial NCT01921296?
This trial is sponsored by Lynn Henry, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.